Bausch+Lomb is to retain over 1,000 jobs and create 100 new roles following a $106-million investment in its manufacturing facility in New York. Around 300 jobs would have been lost if the company had moved this new manufacturing line out of the U.S. Two manufacturing lines will be created and extensive interior rebuilding will be undertaken. This is expected to allow the company to expand its core manufacturing and distribution services and increase capacity for a new silicone hydrogel contact lens product. The investment benefited from an incentive package provided by the state of New York. Valeant Pharmaceuticals International acquired the company for $8.7 billion in August.